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Given current evidence, the effect of left ventricular assist device (LVAD) 
implantation on pulmonary function tests remains controversial.
AIM 
To better understand the factors contributing to the changes seen on pulmonary 
function testing and the correlation with pulmonary hemodynamics after LVAD 
implantation.
METHODS 
Electronic databases were queried to identify relevant articles. The summary 
effect size was estimated as a difference of overall means and standard deviation 
on a random-effects model.
RESULTS 
A total of four studies comprising 219 patients were included. The overall mean 
forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and 
diffusion lung capacity of carbon monoxide (DLCO) after LVAD implantation 
were significantly lower by 0.23 L (95%CI: 0.11-0.34, P = 00002), 0.18 L (95%CI: 
0.03-0.34, P = 0.02), and 3.16 mmol/min (95%CI: 2.17-4.14, P < 0.00001), 
respectively. The net post-LVAD mean value of the cardiac index was 
significantly higher by 0.49 L/min/m2 (95%CI: 0.31-0.66, P < 0.00001) compared to 
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pre-LVAD value. The pulmonary capillary wedge pressure and pulmonary 
vascular resistance were significantly reduced after LVAD implantation by 8.56 
mmHg (95%CI: 3.78-13.35, P = 0.0004), and 0.83 Woods U (95%CI: 0.11-1.55, P = 
0.02), respectively. There was no significant difference observed in the right atrial 
pressure after LVAD implantation (0.61 mmHg, 95%CI: -2.00 to 3.32, P = 0.65). 
Overall findings appear to be driven by studies using HeartMateII devices.
CONCLUSION 
LVAD implantation might be associated with a significant reduction of the 
spirometric measures, including FEV1, FVC, and DLCO, and an overall 
improvement of pulmonary hemodynamics.
Key Words: Pulmonary function tests; Left ventricular assist device; Spirometry; 
Ventricular assist device
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Left ventricular assist device (LVAD) implantation can cause worsening of 
forced expiratory volume in one second, forced vital capacity, and diffusion lung 
capacity of carbon monoxide in post-LVAD patients. However, the benefits of LVAD 
implantation outweigh its risks in the context of pulmonary hemodynamics. More large 
scale studies are required to validate our findings.
Citation: Ullah W, Meizinger C, Ali Z, Panchal A, Saeed R, Haas DC, Rame E. Effects of left 
ventricular assist device on pulmonary functions and pulmonary hemodynamics: A meta-




Since the advent of the left ventricular assist device (LVAD) in 1988, literature has 
appropriately focused on its survival benefits in heart failure patients[1,2]. Over the 
years, with an increase in its use, many LVAD related complications also started 
surfacing together. Arena et al[3] in 1999 were the first to present data, implicating a 
decrease in spirometric measures in patients with LVAD implantation. These 
observation was based on the comparison of pre and post-LVAD findings in a 58-year 
old gentleman[3]. Later on, more observational studies attempted to elucidate the 
complex interplay of pathophysiological dynamics between LVAD and pulmonary 
system, but had conflicting findings[4-7]. Until recently, there has been no concrete 
evidence in the form of a randomized controlled trial (RCT) or meta-analysis to 
identify the net clinical benefit of LVAD in the context of worsened pulmonary 
functions and improved pulmonary hemodynamics.
MATERIALS AND METHODS
Search strategy and study collection
A literature search was performed up to December 2019, using PubMed, EMBASE, 
and Cochrane databases. There was no language or time restriction. The search 
strategies included various combinations of medical subject headings (MeSH) to 
generate two subsets of citations: One for LVAD and other for pulmonary function 
tests (PFTs). The terms from the two subsets were combined in 1:1 combination using 
boolean operators, and results from all possible combinations were screened for 
relevant articles. Based on our research question, articles from the reference lists 
pertinent to the clinical question were also evaluated by an independent author 
(backward snow bowling). Studies comparing changes in PFTs and pulmonary 
hemodynamics after LVAD implantation were included in the final analysis. 
Ullah W et al. Effect of LVAD on PFTs
WJC https://www.wjgnet.com 552 November 26, 2020 Volume 12 Issue 11
Pulmonary hemodynamics included cardiac output (CO), right atrial pressure (RAP) 
and pulmonary capillary wedge pressures (PCWP) assessment; pulmonary vascular 
resistance (PVR) was calculated by the standard formula PVR = (mPAP - PCWP)/CO. 
The studies with insufficient data, case reports, review articles, and conference papers 
were excluded after detailed discussion (Figure 1).
Quality of included studies
The overall methodological quality of the included studies was low. Due to the 
inclusion of single-center retrospective studies, the risk of selection bias could not be 
assessed. Similarly, randomization and allocation concealment of the subjects at the 
level of individual study could not be performed. Most studies, however, mentioned 
the baseline characteristics of the included population except by Imamura et al[5]. The 
risk of reporting bias across all studies was minimal due to adequate reporting of 
outcomes. Only patients who had post-LVAD spirometry measurements were 
included in the study, minimizing the risk of attrition bias. All included studies used a 
self-control model in which the same population was assessed before and after an 
intervention (LVAD implantation); hence, the risk for detection bias was negligible. 
The detailed and summary bias graphs are given in Figure 2.
Statistical analysis
The statistical analysis was performed using the random-effects model (inverse 
variance) to calculate the mean difference and SD for continuous variables. The 
probability value of P < 0.05 was considered statistically significant. The “test for 
overall effect” was reported as z value corroborating the inference from the 95%CI. 
Higgins I-squared (I2) statistic model was used to assess variations in outcomes of the 
included studies. I2 values of 50% or less corresponded to low to moderate, and 75% or 
higher indicated large amounts of heterogeneity. Publication bias was illustrated 
graphically using a funnel plot. The quality assessment of the included articles was 
performed using the Cochrane guidelines for the systematic review and meta-analysis, 
where each study was screened for five different types of bias (selection, performance, 
detection, attrition, and reporting bias). All statistical analysis was performed using 
the Cochrane Review Manager (RevMan) version 5.3.
RESULTS
Search results and study selection
The initial search on multiple databases revealed 1086 articles. After removal of 
irrelevant and duplicate items, 132 articles deemed relevant for full-text review. We 
further excluded 128 articles based on our selection criteria. Multiple attempts to 
authors to retrieve data were unsuccessful. Four articles qualified for final analysis[4-7]. 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
flow diagram is shown in Figure 1.
A total of 219 patients, with a mean age of 54 ± 11 years, were included. About 73% 
of the included subjects were males. Two thirds (74%) of the overall population had 
2nd generation continuous flow devices (HeartMateII), while 26% of patients had a 3rd 
generation pulsatile flow device (HeartWare). The overall mean basal metabolic index 
was 26 ± 12 kg/m2. The mean left ventricular ejection fraction was 10%. The 
indications for LVAD implantation were non-ischemic and ischemic cardiomyopathy 
in 62% (136/219) and 36% (79/219) of patients, respectively. Sajgalik et al[6] were the 
only ones reporting hypertrophic cardiomyopathy in four patients. The functional 
status of the included population was defined either by a 6-min walk test (Raheja et al[7]
) or by classification of the New York Heart Association (NYHA) (Sajgalik et al[6]). The 
mean brain nitric peptide level was 1695 pg/mL. Of the reported comorbidities, 
diabetes, chronic kidney disease, and hypertension were the most common. 
Approximately 22% (50/219) of the total population carried a diagnosis of chronic 
obstructive lung disease (COPD). The mean follow-up duration and timing of post-
LVAD spirometry ranged from 6 mo to 12 mo. The detailed study characteristics are 
given in Supplementary Table 1.
Pooled estimate of spirometric changes with LVAD implantation
The overall mean forced expiratory volume in one second (FEV1) and forced vital 
capacity (FVC) values were significantly lower after LVAD implantation by 0.23 L 
(95%CI: 0.11-0.34, P = 00002) and 0.18 L (95%CI: 0.03-0.34, P = 0.02), respectively. The 
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Figure 1  PRISMA flow diagram of the included studies.
Figure 2  Detailed methodological quality and bias assessment of included studies.
heterogeneity among the outcomes of the included studies was minimal for both FEV1 
and FVC with an I2 = 0% (P = 0.98 and P = 0.75, respectively) (Figure 3A and B). The 
overall mean value of ΔDLCO (diffusion lung capacity of carbon monoxide) was 
robustly reduced by 3.16 mmol/min (95%CI: 2.17-4.14, P < 0.00001) in the post-LVAD 
state. There was no heterogeneity among the outcomes of individual studies I2 = 0% (P 
= 0.59) (Figure 3C).
Pooled estimate of pulmonary hemodynamics with LVAD implantation
All indices of pulmonary hemodynamic observed an overall improvement with LVAD 
implantation. The net post-LVAD implantation mean cardiac index was significantly 
higher by 0.49 L/min/m2 (95%CI: 0.31-0.66, P < 0.00001) compared to pre-LVAD 
values with no heterogeneity (I2 = 0). Imamura et al[5] study contributed more than half 
to the overall effect size (52% weight) (Figure 4A). Compared to pre-LVAD values, the 
pooled estimate of PCWP and PVR was significantly reduced after post-LVAD 
implantation by 8.56 mmHg (95%CI: 3.78-13.35, P = 0.0004), and 0.83 Woods U (95%CI: 
0.11-1.55, P = 0.02), respectively (Figure 4B and C). There was no significant difference 
observed in RAP in the post-LVAD cohort both at the study level and in the pooled 
analysis (0.61 mmHg, 95%CI: -2.00 to 3.32, P = 0.65). The heterogeneity among the 
included studies was moderate (I2 = 76%, I2 = 42%, I2 = 57%, respectively) (Figure 4D).
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Figure 3 Forest plot depicting the pooled mean difference of forced expiratory volume in one second (A), forced vital capacity (B) and 
diffusion lung capacity of carbon monoxide (C) between pre- and post-left ventricular assist device patients. FEV1: Forced expiratory volume 
in one second; FVC: Forced vital capacity; DLCO: Diffusion lung capacity of carbon monoxide; LVAD: Left ventricular assist device.
DISCUSSION
Our meta-analysis shows a substantial decrease in the overall mean spirometric 
measures (FEV1, FVC, FEV1/FVC, and DLCO) in post-LVAD patients. The pulmonary 
hemodynamics were, however, significantly improved with an overall mean decrease 
in the PCWP and PVR. As expected, post-LVAD patients observed a substantial 
improvement in the cardiac index. Together these changes represented a net decrease 
in left ventricular filling pressure and an improvement in the left ventricular function. 
There was no effect seen on the net difference of RAP in patients following LVAD 
implantation. The detailed pre- and post-LVAD spirometric metrics are given in 
Figure 5.
Many factors could be accounted for the restrictive pulmonary pattern seen in post-
LVAD patients. The initial transient decline in PFTs (FVC and FEV1) could be 
attributed to anesthesia effects or respiratory muscle weakness due to the major 
cardiothoracic surgery[4]. Long term decrease in post-LVAD FVC can partly be 
explained by an LVAD patient now having an object that occupies approximately 50 
mL (HeartWare) to 63 mL (HeartMateII) of intrathoracic space[4]. In addition to the 
anatomical limitations, a constellation of mechanical and physiological mechanisms 
compromises the diaphragmatic functions, such as surgical implantation of 
HeartMateII below the diaphragm, sternotomy, thoracic scaring and respiratory 
muscle weakness due to cardiac cachexia[7]. Moreover, heart failure induced reactive 
fibrosis, pleural effusion, and cardiomegaly can worsen the post-LVAD spirometric 
measures by mechanically impeding the lungs from expanding[6]. Heart failure can 
also incite bronchial hypersensitivity or can cause interstitial edema, and compressive 
atelectasis, further compromising the spirometric metrics of post-LVAD patients. Some 
post-LVAD patients are at high risk of decline in spirometric measures if they have a 
compelling indication for pneumotoxic medications such as amiodarone[4-7].
The literature on the post-LVAD pulmonary dynamics is scarce. Our extensive 
literature search identified four studies for quantitative analysis[4-7]. All these studies 
unanimously agreed on the decline of pulmonary functions and the improvement of 
pulmonary hemodynamics in post-LVAD patients. These studies, however, should be 
interpreted in the context of its methodological limitations. Most studies used older 
generation devices (HeartMateII), while more contemporary studies used the newer 
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Figure 4 Forest plot showing pooled comparison of mean difference in cardiac index (A), pulmonary capillary wedge pressures (B), 
pulmonary vascular resistance (C), and right atrial pressure (D) between pre- and post-left ventricular assist device groups. PCWP: 
Pulmonary capillary wedge pressures; PVR: Pulmonary vascular resistance; RAP: Right atrial pressure; LVAD: Left ventricular assist device.
generation pulsatile LVAD devices (HeartWare). This potentially skewed the overall 
results of the studies. Mohamedali et al[4] in 2015, were the first to recognize that a 
decrease in the spirometric measures (FEV1, FVC, and DLCO) was actually driven by 
the HeartMateII devices, rather than HeartWare. They attributed these findings to the 
surgical resection related paralysis of the diaphragm, post-procedure lung fibrosis, 
and restriction of the left hemidiaphragm by a relatively larger device size in the 
former[4]. Raheja et al[7] subsequently validated the overall results of the prior study. 
They also quantified the effect of LVAD on the functional status of heart failure 
patients using a six-minute walk distance (MWD). A significant correlation between 
the MWD and LVAD induced change in FEV1 (P = 0.0466), and DLCO (P = 0.0032) 
was demonstrated; however, these findings were never adjusted for the duration of 
follow up[7]. Sajgalik et al[6] hurdled these limitations by performing a stratified analysis 
based on different follow-up durations. Although a substantial amount of decline in 
FEV1 (P = 0.04) and FVC (P = 0.01) was observed at 12-mo, there was no significant 
decrease in PFTs on a shorter follow-up duration of 6-mo (FVC P = 0.07, FEV1 P = 
0.27). Similarly, the observed predictive effect of survival with the change of DLCO at 
6-mo (P = 0.03) was attenuated at an extended follow-up duration of 12-mo (P = 
0.22)[6].
Mohamedali et al[4] exclusively used the 2nd generation (HeartMateII) devices, while 
about 77% LVADs in the Sajgalik et al[6] and 88% of devices used by Raheja et al[7] study 
were HeartMateII devices. Despite a higher percentage of HeartMateII devices in the 
later studies, the overall outcomes were never stratified based on the device type[5-7]. 
Therefore, a clear distinction between the relative safety of HeartMateII and 
HeartWare could not be ascertained. This, along with the fact that all studies had 
substantial limitations due to non-randomized data, call into question the 
generalizability of individual results.
One can also argue that spirometric changes observed in post-LVAD patients could 
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Figure 5 Trend of decrease in forced expiratory volume in one second (A), forced vital capacity (B), and diffusion lung capacity of carbon 
monoxide (C) in the included studies. FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; DLCO: Diffusion lung capacity of carbon 
monoxide; LVAD: Left ventricular assist device.
be a transient decline of the pre-existing lung disease, and might not have long-term 
consequences. As claimed by Imamura et al[5] in his analysis, that the post-LVAD PFTs 
worsening is a reversible phenomenon with heart transplantation. However, more 
studies are needed to shed light on the long-term impacts of LVAD implantation on 
pulmonary dynamics. It should also be noted that, approximately 36% of patients from 
Sajgalik et al[6] study had obstructive sleep apnea, while 29% of patients in Mohamedali 
et al[4], and 22% of Raheja et al[7] patients had COPD. It is unclear if the decrease of post-
LVAD spirometric measures in the mentioned cohorts was an actual device effect or 
was merely worsening of their underlying lung condition.
Given apparent differences in the outcomes and significant effect of covariates on 
the results, one should be cautious about the clinical interpretations of individual 
results. This, along with the fact that previous small studies were either underpowered 
to detect clinical outcomes, or had conflicting findings, prompted us to integrate the 
findings of these studies.
In contrast to individual data, our meta-analysis provides strong evidence that 
LVAD related beneficial effects outweigh its potential spirometric decline in heart 
failure patients. A minimal mean decrease in post-LVAD measures of FEV1 and FCV 
by only 0.23 L and 0.18 L respectively is massively offset by a significantly higher 
increase in the cardiac index by 0.49 L/min/m2, and improvement of PCWP by 8.56 
mmHg and PVR by 0.83 Woods U, respectively. Our meta-analysis also illustrates the 
paucity of randomized data in post-LVAD patients and highlights the limits on our 
ability to draw definitive conclusions due to the retrospective nature of data.
Our study is constrained by the limitations of the available data. A significant 
barrier was our inability to perform a stratified subgroup analysis based on different 
LVAD types and variable follow up durations. The inherent heterogeneity in the 
inclusion criteria of studies could not be accounted for in the pooled analysis. This, in 
addition to the biases and confounding factors inherent in observational non-
randomized studies, call for caution when interpreting the results of this meta-
analysis.
To determine the actual effect of LVAD implantation on spirometric metrics, it is 
imperative to account for all the confounding variables in a controlled population. One 
way would be to determine the causation of lung findings on a prospective scale or 
conduction of a RCT. This will enable the researchers not only to assess the risk of 
post-LVAD spirometric changes but can also help in the identification of instantaneous 
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event rates such as mortality and survival benefits.
CONCLUSION
LVAD implantation might be associated with worsening of FEV1, FVC, and DLCO in 
post-LVAD patients. However, the overall benefits of LVAD in the context of 
pulmonary hemodynamics outweigh the presumed harm to spirometric metrics. 
More large scale studies are needed to validate our findings.
ARTICLE HIGHLIGHTS
Research background
Recent studies suggest that left ventricular assist device (LVAD) implantation has not 
been associated with an improvement in pulmonary function tests. However, the 
improvement seen in post-LVAD pulmonary hemodynamics outweighs the observed 
decrease in spirometry.
Research motivation
The studies investigating these parameters are not expansive and the overall 
methodological quality of the studies available is low. Further inquiry into the effects 
of the LVAD implantation on pulmonary hemodynamics, objective pulmonary 
function testing and on the observed clinical outcomes is needed.
Research objectives
This meta-analysis aims to stratify the observed outcomes in studies assessing these 
parameters, in order to better understand the factors contributing to the changes seen 
on pulmonary function testing and the correlation with pulmonary hemodynamics.
Research methods
Our study literature search was performed on published data until December 2019, 
using PubMed, EMBASE, and Cochrane databases. After screening the studies 132 
articles deemed relevant were reviewed. 128 articles were excluded based on our 
selection criteria. Four studies were analysed and included in this meta-analysis.
Research results
A total of four studies comprising 219 patients were included. The overall mean forced 
expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion 
lung capacity of carbon monoxide (DLCO) after LVAD implantation were significantly 
lower by 0.23 L (95%CI: 0.11-0.34, P = 00002), 0.18 L (95%CI: 0.03-0.34, P = 0.02), and 
3.16 mmol/min (95%CI: 2.17-4.14, P < 0.00001), respectively. The pulmonary capillary 
wedge pressure and pulmonary vascular resistance were significantly reduced after 
LVAD implantation by 8.56 mmHg (95%CI: 3.78-13.35, P = 0.0004), and 0.83 Woods U 
(95%CI: 0.11-1.55, P = 0.02), respectively. There was no significant difference observed 
in the right atrial pressure after LVAD implantation (0.61 mmHg, 95%CI: -2.00 to 3.32, 
P = 0.65).
Research conclusions
LVAD implantation might be associated with a significant reduction of the spirometric 
measures, including FEV1, FVC, and DLCO, and an overall improvement of 
pulmonary hemodynamics.
Research perspectives
The short term and long-term effects of LVAD on the pulmonary hemodynamics on 
and pulmonary function tests need to be expanded and are essential in order to better 
assess outcomes. The need for randomized control trials exists to identify confounding 
factors that may affect the outcomes seen in the studies analyzed. Also, further studies 
with extended follow-up are needed to assess the clinical outcomes of the changes 
seen on PFTs and hemodynamics.
Ullah W et al. Effect of LVAD on PFTs
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